Eupraxia Pharmaceuticals Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James A. Helliwell
- Full Time Employees
- 49
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2067 Cadboro Bay Road Victoria BC Canada V8R 5G4
- IPO Date
- Apr 5, 2024
- CIK
- 0001581178
- Website
- eupraxiapharma.com
- Similar Companies
- Business
- Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX; TSX:EPRX) is a clinical-stage biotechnology company that develops locally delivered, extended-release therapeutics using its proprietary DiffuSphere technology platform to enable targeted drug delivery for inflammatory diseases, pain, gastrointestinal disorders and oncology. The company's lead product candidate, EP-104GI, targets eosinophilic esophagitis through esophageal wall injections providing sustained anti-inflammatory effects; EP-104IAR addresses knee osteoarthritis pain via intra-articular delivery; its pipeline also encompasses additional musculoskeletal, gastrointestinal and oncology indications leveraging DiffuSphere to enhance efficacy, duration and safety of approved drugs by minimizing systemic exposure. Founded in 2011 and headquartered in Victoria, British Columbia, Canada, Eupraxia operates primarily in North America with clinical programs focused on high-unmet-need patient populations in the US and global markets. Recent developments include closing a US$80.5 million public offering in September 2025 to fund the Phase 2b RESOLVE trial for EP-104GI with topline data expected in the third quarter of 2026; positive 12-month Phase 1b/2a data in September 2025 showing two-thirds of high-dose patients in clinical remission and sustained tissue improvements; dosing the first patient in the placebo-controlled Phase 2b RESOLVE portion in August 2025; and reporting cash reserves of $89.0 million as of September 30, 2025 following an earlier non-brokered private placement.
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
New Strong Sell Stocks for April 2nd
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
Ally Bridge Group NY LLC Buys New Shares in Eupraxia Pharmaceuticals Inc. $EPRX
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
Eupraxia Pharmaceuticals Announces Proposed Public Offering
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results